Baylor Charles A. Sammons Cancer Center at Dallas Blood ... Chontos_sample blood... · Cellular therapy of cancer remains a cornerstone of treatment for patients with hematologic

Baylor Charles A. Sammons Cancer Center at Dallas

Blood and Marrow Transplant Services

Celebrating 30 Years and 4,800 Blood and Marrow Transplantations

Program Highlights•Morethan4,800transplantationsperformedsinceprograminceptionin1983

• Texas’firstunrelateddonorbonemarrowtransplantationwasperformedbythetransplantphy-siciansonthemedicalstaffatBaylorCharlesA.SammonsCancerCenteratDallasin1988

• ContinuouslyaccreditedbytheFoundationfortheAccreditationofCellularTherapy(FACT)since1998

• AmonganelitegroupoffacilitiesdesignatedasaCenterofExcel-lenceinmostmajorinsurancenetworksformeetingstrictqualityofcarestandards

• AccordingtotheCenterforInternationalBloodandMarrowTransplantResearchandthe

NationalMarrowDonorProgram®(NMDP),ofthetop10nationaltransplantationprograms(innumberoftransplants),BaylorSammonsCancerCenteratDallasroutinelyacceptspatientswithhighercomplexitywithresultsthatexceedexpectations

Did You Know? Transplantationisastandardofcarefor:• acuteandchronicleukemias• high-riskrelapsedlymphomas•multiplemyeloma• relapsedtesticularcancer• sicklecellanemia• bonemarrowfailuresyndromes•MDS• aplasticanemia

Today,patientsuptoage75inotherwisegoodhealthareconsider-edfortransplantation.Olderpatientsmayalsobeconsideredafterdiscus-sionwiththetransplantteam.

How to ReferTo refer a patient, please call 214.370.1500.

Pleasebeassuredthatourinvolve-mentwithyourpatientswillbetoinformanddirectthemtoappropri-atestudiesortransplantationoptions.Atyourdirection,wewillseethepatientsandreviewtheclinicaltrial/transplantationprocesswiththem.Ifthepatientswishtoparticipate,wewillobtaininformedconsentandproceedwiththerequiredclinicaltrial/transplantationprocedures.Wewillpersonallyupdateyouontheirprogressthroughouttheprocessandattheendoftheclinicaltrial/transplanta-tiontreatment.Thepatientswillthenbereferredbacktoyou,alongwithawrittenreportoftheirprogressinthestudy,generalhealthconditionandpublishedguidelinesregardingpost-transplantationmanagement.

Is my patient suitable for transplantation?Learn more by speaking to a blood and marrow transplant physician on the medical staff at Baylor Charles A. Sammons Cancer Center at Dallas. Please call 214.370.1500.

DearColleague,

Theimportanceofthehumanimmunesysteminfightingcancerwasemphasizedin2011whentheprestigiousNobelPrizeinPhysiologywasawardedtothreerenownedimmunologists:BruceBeutler,MD,andJulesHoffmann,PhD,whodiscoveredhowtoactivateinnateimmunity,andRalphSteinman,MD,whodiscoveredthedendriticcellanditsroleinadaptiveimmunity.

Cellulartherapyofcancerremainsacornerstoneoftreatmentforpatientswithhematologicmalignanciessuchasleukemia,lymphomaandmultiplemyeloma.Sinceitsinceptionin1983,theBloodandMarrowTransplantProgramatBaylorUniversityMedicalCenteratDallashasbeen“wieldingtheimmunesword”inthefightagainstcancer.Withcontinuedrefinement,throughclinicalandbasicresearch,thebladehasbeensharpenedandpotentiallycurativetherapycannowbeofferedtoselectedpatientsintotheir70s(Sorror,etal, JAMA.2011;306(17):1874-1883).

Ifyoutreatadultswithacuteleukemia,itisessentialtoobtaingeneticandmolecularprognosticfactorsatdiagnosistoiden-tifyearlythosepatientswhowillclinicallybenefitfromsubsequentallogeneictransplantation. Modernmethods(FISHpanels,PCRdetectionofmutantgenes)obviatetheproblemswhichusedtoplaguestandardcytogenetictesting.Themostvaluablefeatureofthesemethodsisprobablytheirrobustness,assamplescanbe3–5daysold.Pendingtheresultsoftheseassays,treatmentcanbeginonweekendsandholidays.

Inaddition,westronglyrecommendpatientsundergoHLAdetermination(tissuetyping)andincludetentativedonoridentifi-cationintheirinitialtreatmentplan.Therationaleissimple:adultleukemiaisdifficulttocure,especiallyifaccompaniedbyadversemolecularorgeneticfeatures.HLAtypingandinformaltransplantationconsultationcanbeeasilyarrangedbycontactingourprogramandspeakingwithoneofthetransplantphysicians.

Autologoustransplantationhasalsomadegreatstridesinthepastthreedecades.Duetoitscurativepotential,itremainsthestandardofcarefortreatingrelapsedHodgkin’sandaggressivenon-Hodgkin’slymphoma.Itisimperativethatthephysicianofferingsalvagetherapycloselyworkswiththetransplantteamtointegratechemotherapycycleswithstemcellcollectionandtoavoiddamagingthestemcellcompartment.Consultationbeforestartingsalvagetreatmentprogramsisinthepatient’sbestinterest.

Multiplemyelomaremainsoneofthemostchallengingofdiseases.Whilemodern“targeted”therapywithagentssuchasbortezomib(Velcade)andlenalidomide(Revlimid)areeffective,theyalsoareexpensive,inconvenientandconfersometimespermanentsideeffectssuchasperipheralneuropathy.Treatmentwithhigh-dosemelphalanandautologousstemcellsupportremainsastandardofcare,bothasa“cap”toinductiontherapyandasasalvageprograminrelapseddisease. Generally,transplantationmaynownotonlybecost-effective,butmayactuallybelessexpensivethanprolongedtherapywith“targeted”drugs.Moreover,qualityoflifeandfreedomfromfrequentvisitstothedoctor’sofficeareamajorpotentialbenefittopatientssotreated.

Autologousimmunotherapy—usinggene-modifiedTeffectorcells—hasrecentlyemergedasanovelandtantalizingapproachtochronicBcelldiseasessuchasCLL(Porter,etal,NEJM.2011;365(8):725-733).Whilesuch“high-tech”approachesarenotyetavailableinthecommunitysetting,theyservetodemonstrateconvincinglythepoweroftheimmunesysteminfightingcancer.Extendingtheanalogyjustabitfurther,onecanimaginesimilarapproachesbeingusedtotreatchronicinfectionssuchasHIV,orevenautoimmunediseasessuchasSLE.

Respectfully,

EdwardAgura,MDMedicalDirector,BoneMarrowTransplantProgram,BaylorUniversityMedicalCenteratDallas

Letter from the Medical Director

BloodandMarrowTransplantServices 1

2 BaylorCharlesA.SammonsCancerCenteratDallas

Does My Patient Need a Donor?Patientswithdiseaseinvolvingthemarrow,suchasacuteleukemia,myelodysplasticsyndromeandbonemarrowfailurestates(e.g.,aplasticanemia)urgentlyneedtofindadonor.Donorsmaybefoundamongfamilymembers,usuallysiblings,orinthevolunteer-relateddonorregistries.Findingadonortakestimeandmoney.Donorsearchesshouldbestartedatthesametimeinitialtreat-mentisbegunorsoonthereafter.

Butnoteverypatientneedstofindadonor.Diseasestreatedwith

Major Indications for Blood or Marrow Transplantation

Disease/Upper Age Limit Stage Type**

Multiplemyeloma/75* following4cyclesofinduction autologous(inmostcases) allogeneic(inselectcases)

Hodgkin’sand inductionfailureoratfirstrelapse autologous(inmostcases)non-Hodgkin’slymphoma/75* beyondrelapse allogeneic(inselectcases) Acutemyeloidand high-riskfirstremission autologous(inmostcases)lymphoidleukemia/75* standardriskfirstremission allogeneic(inselectcases) remissionrelapseor2nd,3rdremissionChronicmyeloid chronicphase(pts>age40mustberesistantleukemia/75* toorintolerantofTKItherapy) allogeneic

Myelodysplastic transfusion—dependentexcessblasts,others allogeneicsyndromes/75*

Chroniclymphocytic fludarabinefailureormultiplelinesoftherapy allogeneicleukemia/75*

Severeaplasticanemia denovoortreatmentfailure allogeneic

Testicularcancer relapsed/refractory autologous

autologoustransplantationincludemultiplemyeloma,mostlymphomatypesandgermcelltumors.

Should I Order Tissue Typing Myself?Youdonotneedtoordertissuetyping.Findingadonorisaspecial-izedandsometimescostlyaspectofallogeneictransplantation.Insurancetypicallypaysforthistesting,butonlyafterapatientisdesignated“transplanteligible.”Thisrequiresaconsultationatatransplantcenter.

Call us for assistance at 214.370.1500.

*Physiologicageandperformancestatuswillbetakenintoconsideration **Autologous=selfdonation **Allogeneic=donorotherthanself

When to Refer Timingisakeyfactorinthesuccessofhematopoieticcelltransplantation.Whileweusesequence-basedHLAtypingtofindthemostcompatiblematch,thisprocesscansometimestakemonthstoyears.Earlyreferralkeepsusfromlosingvaluabletimeinthiscriticalsearchandpotentiallyimprovesoutcomes.Thefollowingguidelinescanbeusedtoidentifypatientsat-riskfordiseaseprogres-sionwhoshouldbeevaluatedforbloodandmarrowtransplantation.


Adult Leukemias and Myelodysplasia Acute Myelogenous Leukemia • High-riskcases,including:– Antecedenthematologicaldisease(suchasmyelodysplasia)

– Treatment-relatedleukemia– Inductionfailure– CR1withpoor-riskcytogeneticsormolecularmarkers

– CR2andbeyond

Acute Lymphoblastic Leukemia • CR1uptoage35• High-riskoverage35,including:– Poor-riskcytogenetics(suchasPhiladelphiachromosome(t(9;22))or11q23rearrangements)

– HighWBC(>30,000–50,000)atdiagnosis

– CNSortesticularleukemia– NoCRwithin4weeksofinitialtreatment

– Inductionfailure– CR2andbeyond

Myelodysplastic Syndromes • Intermediate-1(INT-1),intermedi-ate-2(INT-2)orhighIPSSscore,whichincludeseither:– >5%marrowblasts– Highriskcytogeneticsornormalwithotheradverseprognosticfactors

– >1lineagecytopenia

Chronic Myelogenous Leukemia • Nohematologicorminorcytoge-neticresponse3monthspost-imatinibinitiation

• Nocompletecytogeneticresponse6to12monthspost-imatinibinitiation

• Diseaseprogression• Acceleratedphase• Blastcrisis(myeloidorlymphoid)

Lymphomas Non-Hodgkin’s Lymphoma• Follicular– Poorresponsetoinitialtreatment– Initialremissionduration<12months

– Secondrelapse– TransformationtodiffuselargeB-celllymphoma

• DiffuseLargeB-Cell– Atfirstorsubsequentrelapse– CR1forpatientswithhighorhigh-intermediateIPIrisk

– NoCRwithinitialtreatment•MantleCell– Followinginitialtherapy

Hodgkin’s Lymphoma• NoinitialCR• Firstorsubsequentrelapse

Multiple Myeloma • Afterinitiatingtherapy• Atfirstprogression

TheseguidelinesfortransplantationconsultationweredevelopedjointlybytheNationalMarrowDonorProgram®(NMDP)andtheAmeri-canSocietyforBloodandMarrowTransplantation.1Theyarebasedoncurrentclinicalpracticeandmedicalliterature,includingcomprehensiveevidence-basedreviews.

InsurancePatientsareguidedthrougheverystepoftheinsuranceprocess.ThetransplantprogramatBaylorUniversityMedicalCenteratDallashasateamoffinancialcounselorswhoscreenfortransplantationser-vicesanddeterminethepatients’financialeligibility.OurprogramisrecognizedasaCenterofExcellencebyUnitedHealthCare,AETNA,andBlueCrossBlueShieldandseekstosupportthepatient’saccesstothehighestlevelofbenefits.

Ifapatienthasbenefitlimitations,weworkwithorganizationssuchastheLeukemia&LymphomaSociety,NationalTransplantFoundationandtheNationalTransplantAssistanceFundtohelpsupplementthepatient’sabilitytopaythecostoftheservices.

Wewillworkcloselywithyoutomaximizeyourpatient’saccesstobenefitsbycoordinatingpayorresourceswithyourpatient’sneeds.

1.Evidence-basedReviews,AmericanSocietyforBloodandMarrowTransplantation.2009.PublishedinBiology of Blood and Marrow Transplantationandavailableonlineat:http://www.asbmt.org.

256 transplantations performed in 2011 alone and more than 4,800 transplantations performed since the program’s inception

Offers comprehensive range of services to treat hematologic cancers, lymphomas, myelomas and marrow failure syndromes

About Our Blood and Marrow Transplant Program


Leif Wennerstrom is a 12-year cancer survivor.

Our FirstsPerformedNorthTexas’firstadultmarrowtransplantationin1983andthefirstmatchedunrelateddonortransplantationin1988.

Blood and Marrow Transplant ResearchInaconstantquestforinnovation,Baylor’sBloodandMarrowTrans-plantProgramhasastrongresearchhistoryandisusuallypartofatleast20studiesatanygiventime.Havingcontributedtotheresearchthat

formstoday’sstandardofcare,we’veturnedourattentiontocreatingthestandardoftomorrow.

Researchincludescellulartherapiesinadditiontoorwithouttransplantation.

Research trials become available frequently, so please contact us at 214.818.8472 for current information. You may also view a list of current clinical trials at BaylorHealth.com/CancerResearch.


Leif Wennerstrom is a 12-year cancer survivor.

Research ConsortiumsBaylorCharlesA.SammonsCancerCenteratDallasisamemberofthefollowingresearchconsortiums:

• CenterforInternationalBloodandMarrowTransplantResearch(CIBMTR).TheCIBMTRcollabo-rateswiththeglobalscientificcommunitytoadvancehematopoi-eticcelltransplantationandcellulartherapyresearchworldwide

• SWOG(formerlytheSouthwestOncologyGroup),oneofthelargestcancerclinicaltrialscoop-erativegroupsintheUnitedStates

• CancerImmunotherapyTrialsNetwork,whichallowstopimmu-nologiststoconductmulticenterresearchonagentsthatboostpatients’ownimmunesystemstofighttheircancer

•MultipleMyelomaResearchConsortium,currentlylimitedto16world-renownedresearchinstitutions,includingCityofHope,Dana-FarberCancerInstituteandMayoClinic.Focusedonearly-stagedrugdevelopment,itpromotescollaborativeresearchbetweenindustryandacademia

• BloodandMarrowTransplantClinicalTrialsNetwork,whichcon-ductsPhaseIIandIIImulticenterclinicaltrials

Our TeamConsumersvotedBaylorSammonsCancerCenteratDallasasthe#1placeforcancercare,asmeasuredbytheNationalResearchCouncil.Thisisatestamenttothehardworkofourmultidisciplinarycancercareteamandeachofthemiscriticaltoyourpatient’scare.Thephysiciansonthemedicalstaffareboard-certifiedininternalmedicine,hematology,oncologyandinfectiousdisease.

Multiple MyelomaResearch Consortium

Powerful Collaboration Accelerates Results

Multidisciplinary teams meet regularly to stay at the forefront of patient care and technology.


The PhysiciansThesevenBMTphysiciansonthemedicalstaffhave130-plusyearsofcombinedexperienceandareapartofTexasOncology. Apioneerincommunity-basedcancercareformorethan25years,TexasOncologyisanindependentpracticededicatedexclusivelytothetreatmentofcancerandblooddisorders.

OurmultidisciplinarycancercareteamisformedbyawidearrayofspecialistsonstaffatBaylorUniversityMedicalCenteratDallas.Dependingontheirdiagnosisandcareplan,yourpatient’scareteammayinclude:

• Chaplain• Dentist• Dentalhygienist

The BMT physicians on the medical staff (from left to right): Carolina Escobar, MD, Edward Agura, MD, BMT Medical Director, Alan M. Miller, MD, PhD, Baylor Chief of Oncology, Robert B. Berryman, MD, Joseph W. Fay, MD, FACP, Luis Piñeiro, MD, FACP, and Estil Vance, MD


• Dermatologist• Educationandsupportstaff• Geneticscounselor• Gynecologiconcologist• Hematologiconcologist• Insurancecoordinator• Integrativetherapist•Medicaloncologist•Musicpractitioner• Oncologydietitian• Oncologynursingteam• Palliativecare• Pathologist• Patientnavigator• Physicaltherapist• Psychologist/counselor• Radiationoncologist• Socialworker• Surgicaloncologist

BE THE MATCH® RegistryBetheMatch®RegistryisthedatabaseofdonorsfortheNationalMarrowDonorProgram®(NMDP).Forthethirdyearinarow,ourprogramrankedfirstoutof46pro-gramsacrossthecountryindonormanagement,aswellasrecruitment.BaylorSammonsCancerCenteratDallasisoneofonlyeightprogramsintheUnitedStates—andtheonlyoneinTexas—toofferallfour

componentsoftheNMDP:adonorcenter,transplantcenter,bonemarrowcollectioncenterandapheresiscollectioncenter.

For more information about the NMDP, please call 214.820.3535.

A patient room in Baylor T. Boone Pickens Cancer Hospital


Medical Education for Blood and Marrow TransplantationBayloroffersaone-yearfellowshipprogramforbloodandmarrowtransplantation.Candidatesshouldhaveprevioussubspecialtytrainingineitherhematologyoroncology.DevelopedspecificallyforPGY6-or7th-yearfellows,theprogramisa50/50blendofdirectclinicalcareandresearch.Successfulcompletionequipsfellowstopracticeinthefield.

Programfellowsgainexperienceinallclinicalaspectsofautologousandallogeneictransplantation,including:• stemcellcollectionmethods• developingchemo/radiotherapytreatmentregimens

• HLAtypinganddonorsearching•managingpost-transplantationcomplications,suchashepaticvenoocclusivedisease,infectionsandgraft-versus-hostdisease

Programresearchisfocusedoncellular-andimmunologic-basedtreatmentsforcancer.Topicscoveredcanalsobeselectedforfurtherstudyduringresearchmonths.Thesetopicsincludedendriticcellvaccines,

regenerativemedicineusinghema-topoieticstemcellsandnoveldrugtherapyofhematologicandotherdiseases.

CarolinaEscobar,MD,thefirstfull-timefellowtocompletetheprogram,shared,“ThebonemarrowstemcelltransplantfellowshipatBaylorwasatrulyenrichingexperience.Ihadtheprivilegeofworkingwithandlearningfromanextraordinarygroupofattendings,asweman-agedpatientswithanunbelievablydiverserangeofpathologyfromtheirinitialconsult,throughouttheactualtransplant,andfinallyintotheirpost-transplantperiod.Throughoutthisprocess,Iwashonoredtobeapartofawonderfultransplantteamconsistingofnursecoordinators,nurses,pharmacists,nutritionists,socialworkers,admin-istratorsandmanyotherswhotrulyawedmewiththeirabilitytocare.Thisfellowshipnotonlytaughtmeagreatdeal,butinspiredmetobepartoftheteam.”

Carolina Escobar, MD

InterestedapplicantsshouldcontactEdwardAgura,MD,medicaldirector,BoneMarrowTransplantProgram,BaylorUniversityMedicalCenteratDallas,[email protected],orAlanMiller,MD,PhD,chiefofoncologyforBaylorHealthCareSystemandmedicaldirector,BaylorSammonsCancerCenteratDallas,[email protected].


Inpatient Care atBaylor T. Boone Pickens Cancer Hospital BaylorT.BoonePickensCancerHospitalisthefirstdedicatedcancerhospitalinNorthTexasandonlythesecondinTexas.Askybridgecon-nectsittoBaylorSammonsCancerCenteratDallas.With48BMTbeds,thenewcancerhospitaldoublestheformerinpatientcapacity.EachroomisICU-equippedandHEPA-filteredandpatientsaretreatedbythesameBMTstaff.

Designedwithmodern,invitinghotel-likedécor,thehospitalfeaturesalargeselectionofartinclinicalareasand

Cancer Care Services

patientrooms.Eachpatient’scom-municationboardisalsoapieceofartandadecorativemagnetboardgivesthemaspacetopersonalizewithget-wellcardsandphotosfromhome.

Largerroomsenablepatientfamiliesandcaregiverstohavetheirownspaceforsitting,sleeping,watchingtelevisionorworkingatadesk.Familiesandcaregiversalsohaveaccesstotwoareasinthehospitalforshowering,washingclothes,workingorrelaxing.

TheOncologyEvaluationandTreatmentCenter(OETC),locatedonthefirstfloorofBaylorCancer

HospitalinSuiteC-1025,providesscheduled,urgent,non-emergencymedicalcarefrom4p.m.to7a.m.MondaythroughThursdayandfrom4p.m.Fridayto7a.m.Monday.Thiscenterwascreatedtoreducethewaitingtimetoreceivecareandforcancerpatientsinneedofurgent,butnotemergencycare,duringweekdayeveninghoursand24/7onweekends,andtohelpreducetheirexposuretocontagiousdiseasesfromothers.Staffmembersaretrainedandknowledgeableaboutthespecificissues,symptomsandsideeffectsrelatedtocanceranditstreat-ments.PatientsarereferredtocareattheOETCbytheironcologist.

Baylor T. Boone Pickens Cancer Hospital


Amenitiespatients,theirfamiliesandcaregiversmightenjoyarelocatedinBaylorSammonsCancerCenteratDallasandinthehospital:

• Forfamiliesandcaregivers,coffeefromacoffeebarandmealsfromtwodiningareas,oneofwhichincludesadeli,gourmetgrillandstationsservingsalad,pizzaandpasta

•Meditationroom• Twohealinggardens• Largechapel

• Teachingkitchen• Specialtyboutiqueofferingitemstominimizethevisibleeffectsofcancertherapy

• AccesstoclinicaltrialsattheInnovativeClinicalTrialsCenter

Outpatient Care Texas Oncology Outpatient BMT ClinicTheTexasOncologyOutpatientBMTClinicoffersmanydiverseservicesdesignedforthebloodandmarrowtransplantationpatient:

• Opensevendaysaweek,365daysayear

• 15examrooms• 18privateinfusionrooms• 16additionalinfusionchairs• Socialworkservices• Fullserviceinfusionandretailpharmacies

• Staffedbynurseswithanaverageof15yearsofexperience

• Pre-transplantationchemotherapy• Post-transplantationcare• Stemcelltransplantscanbeperformedintheoutpatientclinicfortheappropriatepatient

Baylor Charles A. Sammons Cancer Center at Dallas


Majoradvancesindrugtherapies,treatmentregimensandtechnologyenablesomepatientstoreceiveatransplantwithoutbeingadmittedtothehospital.Patientsreceivingout-patientcarereceivealltheservicesofaninpatientunit,suchastransfu-sions,chemotherapy,antibioticandphysicianconsultation.Patientswholivenearthefacilitycanstayintheirownhomes,travelingbackandforthtotheclinicfortreatments.Patientslivingfurtherawayareprovidedwithanumberofhousingoptionsthatareappropriatefortheirfinancialneed.

Patient Navigation ProgramAfteracancerdiagnosis,patientscanfeeloverwhelmedbyallthephysicianspecialiststheyneedtoseeandallthedecisionstheyhavetomake.That’swhyeverypatientwhowalksthroughourdoors,ishelpedeachstepofthewaybytheirownpatientnavigator,anexperiencedhealthcareprofessionalwhoguidespatientsandfamiliesthroughtheprocessofcancercare.Navigatorshelppatientsby:

• schedulingappointments• gatheringmedicalrecords• coordinatingreferralstocancerspecialists

• keepingtrackoftheirtreatmentprogress

• providinginformationoncancerresearchtrials

• simplifyingaccesstoservicessuchaseducation,supportandidentifi-cationofavailableresources

To contact a patient navigator, please call 214.820.3535.

Dental Clinic TheDentalClinictreatspre-andpost-transplantationpatientswhoneedoralcare.Dentaloncologygoesbeyondthescopeofgeneraldentaltreatment,managingsofttissuesofthemouthandcaringfortheoralsideeffectsofcancertherapy.Italsoemphasizesoralcancerpreventionandearlydetection.TheDentalClinicisopenfrom8:30a.m.to3:30p.m.,MondaythroughFriday.

To schedule appointments, call 214.820.3535.

FitSteps for Life®

TheFitStepsforLife®freeprogramismanagedbytheCancerFoundationforLife®andhelpsyourpatientsimprovetheirphysicalwell-beingthroughexerciseduringandaftercancertreatment.Trainedstaffmemberscreateaprogramtailored

specificallytoyourpatient’sfitnesslevel,needsandgoals.

For more information, call 214.820.3535.

Patient Education and Support TheVirginiaR.CvetkoPatientEducationandSupportCenterofferspatientsaplacetosharetheirexperi-enceandlearnfromothersurvivors.Theprofessionalstaffhelpspatientsandtheirlovedonesunderstandandmanagethechallengesofcancer.

PatientscanturntotheCvetkoCenterforcriticalresourcesforeveryaspectoftheirjourney,including:

• spiritualandemotionalsupport• homecare• communityresources• cookingclassesfortheuniquenutritionalneedsofcancerpatients

• “artcart”thatbringsartactivitytotheBMToutpatientarea

• therapeuticmusicprogram,inwhichcertifiedmusicpractitionersuseliveandacousticmusictoaidpatientswhoarefacingphysical,emotionalandspiritualchallenges


Servicesarefreeandgrantaccessto:

• professionalstaff,includingRNs,aclinicalpsychologist,chaplainsandsocialworkers

• generalanddisease-specificeducationfortheindividualandforgroups

•monthlysupportprograms• resourcelibrarywithInternetaccess,books,educationalmaterialsandDVDs

HousingAllpatientswholiveoutsidea50-mileradiuswillbeevaluatedfortheirneedsandmatchedwithsuitablehousingoptions.InadditiontoBaylorPlazaHotelandArcHouse,patientscanhaveaccesstootherhousingoptions.AsiteclosetoBaylorSammonsCancerCenteratDallashasbeenchosenasafuturelocationforanAmericanCancerSocietyHopeLodge.Planningisinprogress.

Twice Blessed HousePatientslivingmorethan50milesfromBaylorSammonsCancerCenteratDallashaveaccesstoaffordable,award-winninghousingatTwiceBlessedHouse.Recognizedforexcel-lencebytransplantationclientsinOptumHealth’sClientChoiceAwardprogram,TwiceBlessedHouseoffers:

• Acommunityof44fullyfurnishedapartmentswherepre-andpost-transplantationpatientsareprovid-edawarmfamilyatmosphereandamenitiesfordailyliving.

• AconvenientlocationafewblocksfromBaylorSammonsCancerCenteratDallas,oneblockawayfromaDARTtrainstopandless

than30minutesfrombothDFWInternationalAirportandDallasLoveFieldairport.ItisalsojustdownthestreetfromBaylorInstituteforRehabilitation,wheresomepatientsmayreceivepost-transplantationrehabilitationtherapy.

• Theopportunityforpatientsandtheircaregiverstobuildrelation-shipswithothertransplantationpatientsthroughcommunityactivi-tiessuchasweeklydinners,artsandcraftnights,gamenights,movienightsandvariousoutings.

Post-Transplantation Ongoing CareCurrently,patientsarescheduledforannualfollow-upvisitsaftertheirtransplantation.Forgreaterconve-nienceforthepatient,thoselivingoutsidetheareaareseenbyreferringphysicians.

CancerpatientsareservedbytheOncologyEvaluationandTreatmentCenter,whichisopenweeknightsandweekends.

3410WorthSt.,Suite570Dallas,TX75246214.820.35351.800.9BAYLORBaylorHealth.edu

Accreditations BaylorSammonsCancerCenteratDallasisaccreditedby:

• FACT,for14consecutiveyears(since1998)

• AmericanCollegeofSurgeonsCommissiononCancer

• TheJointCommission

Notably,BaylorUniversityMedicalCenteratDallashasbeenreaccred-itedasaMagnet®hospitalbytheAmericanNursesCredentialingAssociation.Fewerthan2percentofthenation’shospitalshaveachievedthisdesignation,whichrecognizeshospitalsthatprovidethehighestlevelofnursingcare.Inaddition,BaylorUniversityMedicalCenteratDallaswasrecentlynamedthe#1hospitalinDallas/FortWorthaccord-ingto US News & World Report.

Making a Transplantation ReferralTo refer a patient, call Texas Oncology Blood and Marrow Transplant Services, at 214.370.1500.

PhysiciansaremembersofthemedicalstaffatoneofBaylorHealthCareSystem’ssubsidiary,community,oraffiliatedmedicalcentersandareneitheremployeesnoragentsofthosemedicalcenters,BaylorUniversityMedicalCenteratDallas,orBaylorHealthCareSystem.Copyright©2012,BaylorHealthCareSystem.Allrightsreserved.SAMMONS_365_2012DH

CancerresearchstudiesonthecampusofBaylorUniversityMedicalCenteratDallasareconductedthroughBaylorResearchInstitute,TexasOncology,andUSOncology.Eachreviews,approves,andconductsclinicaltrialsindependently.

12221MeritDr.,Suite500Dallas,TX75251214.370.15001.888.864.ICAN(4226)texasoncology.com

Candice Stinnett celebrates every day of her life with husband, John, and their son, Jonathan.

Baylor University Medical Center at Dallas Campus Map

Healing Garden

Underground Parking Garage

Lot 25

Underground Parking

Garage 8

(Staff)(Patient/Visitorand Staff)(Patient/Visitor)

Parking Garage 4

WorthStreetTower

Underground Parking Garage 30



Lot 44

Lot 43

Lot 40Lot 41

Lot 42

Lot 13Lot 14

Lot 19

Lot 46

Lot 27Lot 28 (BIR

only)

Lot 9

Lot 26

Lot 9

Baylor Tom LandryFitness Center

BaylorSchool

of NursingBass

Hall

BaylorInstitute for

Rehabilitation(BIR)

Parking Garage 10

BaylorMedicalPavilion

ParkingGarage 6

ParkingGarage 5

Baylor Hamilton Heart & Vascular Hospital

Emergency Department

Barnett Tower

WadleyTower Baylor College

of Dentistry

Roberts Hospital

JonssonHospital

HoblitzelleHospital

Truett Hospital

Baylor Charles A. Sammons

Cancer CenterW

ashi

ngto

n Av

enue

Was

hing

ton

Aven

ue

Junius Street

Nussbaumer Street

Floyd Street

Malcolm X Blvd.

Hall

Stre

etHa

ll St

reet

Floyd Street

Gaston Avenue

CBD Link–Fair Park Blvd.

Gaston Avenue

Junius Street

Worth Street

Crutcher Street

Victor Street

Paul

ine

Stre

et

Self Parking

Valet Parking

(Staff)

BaylorT. Boone Pickens

Cancer Hospital

214.820.35351.800.9BAYLORBaylorHealth.edu

214.370.15001.888.864.ICAN(4226)texasoncology.com

Documents

Baylor Charles A. Sammons Cancer Center at Dallas Blood ... Chontos_sample blood... · Cellular therapy of cancer remains a cornerstone of treatment for patients with hematologic